Holmström MO - Search Results

1

Novel Strategies for Peptide-Based Vaccines in Hematological Malignancies.

Klausen U, Holmberg S, Holmström MO, Jørgensen NGD, Grauslund JH, Svane IM, Andersen MH. Klausen U, et al. Among authors: holmstrom mo. Front Immunol. 2018 Oct 1;9:2264. doi: 10.3389/fimmu.2018.02264. eCollection 2018. Front Immunol. 2018. PMID: 30327655 Free PMC article. Review.

2

The CALR exon 9 mutations are shared neoantigens in patients with CALR mutant chronic myeloproliferative neoplasms.

Holmström MO, Riley CH, Svane IM, Hasselbalch HC, Andersen MH. Holmström MO, et al. Leukemia. 2016 Dec;30(12):2413-2416. doi: 10.1038/leu.2016.233. Epub 2016 Aug 18. Leukemia. 2016. PMID: 27560107 No abstract available.

3

The JAK2V617F mutation is a target for specific T cells in the JAK2V617F-positive myeloproliferative neoplasms.

Holmström MO, Hjortsø MD, Ahmad SM, Met Ö, Martinenaite E, Riley C, Straten P, Svane IM, Hasselbalch HC, Andersen MH. Holmström MO, et al. Leukemia. 2017 Feb;31(2):495-498. doi: 10.1038/leu.2016.290. Epub 2016 Oct 20. Leukemia. 2017. PMID: 27761006 No abstract available.

4

The calreticulin (CALR) exon 9 mutations are promising targets for cancer immune therapy.

Holmström MO, Martinenaite E, Ahmad SM, Met Ö, Friese C, Kjær L, Riley CH, Thor Straten P, Svane IM, Hasselbalch HC, Andersen MH. Holmström MO, et al. Leukemia. 2018 Feb;32(2):429-437. doi: 10.1038/leu.2017.214. Epub 2017 Jul 5. Leukemia. 2018. PMID: 28676668

5

Sorted peripheral blood cells identify CALR mutations in B- and T-lymphocytes.

Kjaer L, Holmström MO, Cordua S, Andersen MH, Svane IM, Thomassen M, Kruse TA, Pallisgaard N, Skov V, Hasselbalch HC. Kjaer L, et al. Among authors: holmstrom mo. Leuk Lymphoma. 2018 Apr;59(4):973-977. doi: 10.1080/10428194.2017.1359743. Epub 2017 Aug 9. Leuk Lymphoma. 2018. PMID: 28792253 No abstract available.

6

The JAK2V617F and CALR exon 9 mutations are shared immunogenic neoantigens in hematological malignancy.

Holmström MO, Hasselbalch HC, Andersen MH. Holmström MO, et al. Oncoimmunology. 2017 Aug 2;6(11):e1358334. doi: 10.1080/2162402X.2017.1358334. eCollection 2017. Oncoimmunology. 2017. PMID: 29147619 Free PMC article.

7

The inhibitory checkpoint, PD-L2, is a target for effector T cells: Novel possibilities for immune therapy.

Ahmad SM, Martinenaite E, Holmström M, Jørgensen MA, Met Ö, Nastasi C, Klausen U, Donia M, Pedersen LM, Munksgaard L, Ødum N, Woetmann A, Svane IM, Andersen MH. Ahmad SM, et al. Oncoimmunology. 2017 Nov 1;7(2):e1390641. doi: 10.1080/2162402X.2017.1390641. eCollection 2018. Oncoimmunology. 2017. PMID: 29308318 Free PMC article.

8

Spontaneous T-cell responses against the immune check point programmed-death-ligand 1 (PD-L1) in patients with chronic myeloproliferative neoplasms correlate with disease stage and clinical response.

Holmström MO, Riley CH, Skov V, Svane IM, Hasselbalch HC, Andersen MH. Holmström MO, et al. Oncoimmunology. 2018 Feb 27;7(6):e1433521. doi: 10.1080/2162402X.2018.1433521. eCollection 2018. Oncoimmunology. 2018. PMID: 29872567 Free PMC article.

9

Cancer immune therapy for myeloid malignancies: present and future.

Holmström MO, Hasselbalch HC. Holmström MO, et al. Semin Immunopathol. 2019 Jan;41(1):97-109. doi: 10.1007/s00281-018-0693-x. Epub 2018 Jul 9. Semin Immunopathol. 2019. PMID: 29987478 Review.

10

Cancer immune therapy for lymphoid malignancies: recent advances.

Klausen U, Jørgensen NGD, Grauslund JH, Holmström MO, Andersen MH. Klausen U, et al. Among authors: holmstrom mo. Semin Immunopathol. 2019 Jan;41(1):111-124. doi: 10.1007/s00281-018-0696-7. Epub 2018 Jul 13. Semin Immunopathol. 2019. PMID: 30006739 Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

52 results

Search Page